• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Eating (Appetite) Disorders - Pipeline Review, H2 2012 Product Image

Eating (Appetite) Disorders - Pipeline Review, H2 2012

  • ID: 2335422
  • November 2012
  • 37 pages
  • Global Markets Direct

Eating (Appetite) Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Eating (Appetite) Disorders - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Eating (Appetite) Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eating (Appetite) Disorders. Eating (Appetite) Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Eating (Appetite) Disorders.
- A review of the Eating (Appetite) Disorders READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Eating (Appetite) Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Eating (Appetite) Disorders 7
Eating (Appetite) Disorders Therapeutics under Development by Companies 9
Eating (Appetite) Disorders Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Eating (Appetite) Disorders Therapeutics – Products under Development by Companies 13
Eating (Appetite) Disorders Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Eating (Appetite) Disorders Therapeutics Development 15
GlaxoSmithKline plc 15
INSYS Therapeutics, Inc. 16
Omeros Corporation 17
Lightlake Therapeutics Inc. 18
Eating (Appetite) Disorders – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
GSK-1521498 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
acamprosate calcium - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
bupropion hydrochloride - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GPR101 Antagonist - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
naloxone hydrochloride - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
dronabinol Intavenous Solution - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Eating (Appetite) Disorders Therapeutics – Drug Profile Updates 31
Eating (Appetite) Disorders Therapeutics - Dormant Products 33
Eating (Appetite) Disorders – Product Development Milestones 34
Featured News & Press Releases 34
Aug 08, 2012: Lightlake Therapeutics Announces Positive Preliminary Phase II Clinical Trial Results Of Binge Eating Disorder Treatment 34
Mar 02, 2011: Omeros Unlocks Orphan GPCRs Linked To Pancreatic Cancer And Cognitive Disorders 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Eating (Appetite) Disorders, H2 2012 7
Products under Development for Eating (Appetite) Disorders – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
GlaxoSmithKline plc, H2 2012 15
INSYS Therapeutics, Inc., H2 2012 16
Omeros Corporation, H2 2012 17
Lightlake Therapeutics Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Eating (Appetite) Disorders Therapeutics – Drug Profile Updates 31
Eating (Appetite) Disorders Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Eating (Appetite) Disorders, H2 2012 7
Products under Development for Eating (Appetite) Disorders – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos